Position in ERAS
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$5,501,200
New position
Shares Held
340,000
first reported quarter
Ownership
0.109%
of shares outstanding
% of Portfolio
4.11%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Position in Biotechnology
Healthcare · as of Mar 31, 2026KVP Capital Advisors, LP holds $131,080,717 across 31 Biotechnology names. ERAS ranks #7 (4.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TERN |
Terns Pharmaceuticals, Inc.
|
440,000 | $23,196,800 | |
| 2 | PRAX |
Praxis Precision Medicines, Inc.
|
42,900 | $13,821,951 | |
| 3 | WHWK |
Whitehawk Therapeutics, Inc.
|
2,165,997 | $7,472,689 | |
| 4 | AXSM |
Axsome Therapeutics, Inc.
|
36,200 | $6,118,524 | |
| 5 | STRO |
Sutro Biopharma, Inc.
|
226,575 | $5,643,983 | |
| 6 | PTGX |
Protagonist Therapeutics, Inc
|
53,000 | $5,586,200 | |
| 7 | ERAS |
Erasca, Inc.
This page
|
340,000 | $5,501,200 | |
| 8 | TRVI |
Trevi Therapeutics, Inc.
|
414,000 | $4,939,020 |
All Filings in ERAS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $5,501,200 | 340,000 | Shares | Sole | 2026-05-13 | |
| No filing history on record for this holder in this stock. | ||||||